Showing 4691-4700 of 9576 results for "".
- Coppertone Whips Up Excitement About New Sunscreen Linehttps://practicaldermatology.com/news/coppertone-whips-up-excitement-about-new-sunscreen-line/2458152/Coppertone is going all out to launch their new Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, including partnering with beauty influencers and the Skin Cancer Foundation. The brand is promot
- Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technologyhttps://practicaldermatology.com/news/alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care/2458197/Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been work
- Save The Dates: ASLMS to Host 37th Annual Conference In Early April 2017https://practicaldermatology.com/news/save-the-dates-aslms-to-host-37th-annual-conference-in-early-april-2017/2458279/American Society for Laser Medicine and Surgery (ASLMS) 2017 will take place April 5 – 9, 2017 in San Diego, Calif. New for 2017 is a special CME Session, Moving from the Lab to the Clinic, which will focus on the translation of technolog
- Encore Dermatology Inc. Launches TridesilonTM (desonide) Cream, 0.05% for ADhttps://practicaldermatology.com/news/encore-dermatology-inc-launches-tridesilontm-desonide-cream-005-for-ad/2458318/Encore Dermatology Inc. is rolling out TridesilonTM (desonide) Cream, 0.05% in a 60g tube for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Encore Dermatology Inc. licensed Tride
- With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realmhttps://practicaldermatology.com/news/with-lifecell-acquisition-allergan-enters-regenerative-medicine-realm/2458341/Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products ALLODERM® and STRATTICETM tissue matrices commonly use
- Study: Partner-Assisted Skin Self-Exams for Melanoma Don't Cause Embarrassmenthttps://practicaldermatology.com/news/study-partner-assisted-skin-self-exams-for-melanoma-dont-cause-embarrassment/2458345/Patients with melanoma may benefit from having their partners help to examine their skin for new skin cancers, and this does not cause embarrassment or discomfort for the patient or partner, finds a new study in
- NPF Offers Open Enrollment Insurance Advice Via New Patient Navigation Centerhttps://practicaldermatology.com/news/national-psoriasis-foundation-offers-open-enrollment-insurance-advice-via-new-patient-navigation-center/2458380/The National Psoriasis Foundation (NPF) Patient Navigation Center aims to help patients l
- Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Submental Fullnesshttps://practicaldermatology.com/news/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-submental-fullness/2458511/The Swedish Medical Products Agency (MPA) gave its thumbs up to Allergan’s BELKYRA® (deoxycholic acid). BELKYRA® is being
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from